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Access to family planning health services in Canada has been historically inadequate and 
inequitable. A potential solution to access barriers appeared when Health Canada approved 
mifepristone, the gold standard for medical abortion, in July 2015. We sought to investigate the 
factors that influence successful initiation and ongoing provision of medical abortion services 
among Canadian health professionals, and how these factors relate to abortion policies, systems, 
and service access throughout Canada. 
 
Methods 
We conducted one-on-one semi-structured interviews with a national sample of abortion providing 
and non-providing physicians and health system stakeholders in Canadian health care settings. Our 
data collection, thematic analysis, and interpretation were guided by Diffusion of Innovation theory.  
 
Results 
We conducted interviews with 90 participants including rural practitioners and those with no 
previous abortion experience. In the course of our study, Health Canada removed mifepristone 
restrictions. Our results suggest that Health Canada’s initial restrictions discouraged physicians 
from practice and were inconsistent with provincial licensing standards, thereby limiting patient 
access. Once de-regulated, remaining factors were primarily related to local and regional 
implementation processes. Participants held strong perceptions that mifepristone was the new 






Health Canada’s removal of mifepristone restrictions facilitated practitioners to implement 
abortion care in primary care settings. Our results are unique as Canada is the first country to 
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Approximately 40% of pregnancies in Canada are unplanned and 1 in 3 Canadian women will have 
at least one abortion in their lifetime.1–4 Access to health services in Canada that enable patients to 
plan and space their pregnancies has been historically inadequate and inequitable.5 Prior to 2017 in 
Canada, abortion services were surgical and provided by fewer than 300 doctors at roughly 100 
facilities in urban cities close to the Canada-US border.4 In this context, patients who lived outside 
large cities had to travel significant distances to access abortion care.6,7 Concern about these 
inequities was expressed in the November 2016 Report of the Committee on Elimination of 
Discrimination Against Women, where The United Nations Human Rights Commissioner called on 
the government of Canada to improve access.5 
 
The approval of mifepristone medical abortion in July of 2015 by Health Canada (the equivalent of 
the U.S. Food and Drug Administration), appeared as a potential solution to improve abortion 
access in primary care settings.8–10 Mifepristone became available for prescription by physicians in 
January 2017. Mifepristone is on the World Health Organization list of essential medicines11 and is 
considered the “gold standard” for medical abortion.  Mifepristone 200 mg oral and misoprostol 
800 mg buccal/vaginal/sublingual is the regimen of choice for medical abortion up to 70 days 
among eligible women.1 Data on use of mifepristone in other nations since 1988 suggests that the 




not with an increase in overall abortion rates.12 Health Canada’s approval of mifepristone9 included 
restrictions, such as mandated physician dispensing and registration with the manufacturer, that 
have contributed to low uptake of mifepristone in primary care in similar high-income nations, 
including the U.S.10,12–15  
 
We hypothesized that Health Canada’s restrictions would impede implementation of mifepristone 
in primary care.16 We also anticipated that stakeholder-reported barriers and facilitators to 
implementation could inform improvements to Canadian abortion policy and practice. This study 
was part of a larger mixed methods investigation.17 In the main study we sought to investigate: 
What are the factors that influence successful initiation and ongoing provision of medical abortion 
services among health professionals, and how do these relate to health policies, systems, and services, 
and to abortion service access throughout Canada? This paper focuses on the first question involving 
what factors influence initiation and provision of medical abortion, from the perspectives of 
Canadian physicians and stakeholders. Our research is a particularly novel contribution to the 
literature as Health Canada repealed its initial restrictions on mifepristone in ‘real time’ over the 
course our study – in October 2016, May 2017, November 2017, and August 2019 (see Box 1). 
These changes made it possible to prescribe and dispense mifepristone the same way as most other 
drugs in Canada. Our study will be relevant to other nations experiencing challenges with access to 
family planning services as Canada is the first to use evidence-based deregulation of mifepristone to 








This national interview study aimed to explore factors that influence implementation of 
mifepristone in Canadian health service delivery and health systems. Our approach was guided by 
Rogers’ Theory of the Diffusion of Innovation,18 as articulated by Greenhalgh19 and Cook.20 This 
qualitative study was a component of a four-year prospective mixed-methods observational 
national program of research on factors that influence implementation of mifepristone in primary 
care, the CART-Mife Study (Contraception and Abortion Research Team-Mifepristone Study). A 
fulsome account of our methods and integrated knowledge translation21 approach for the entire 
study can be found in our research protocol.17 Our survey data collection is ongoing and not 
reported in the present study. Our approach was guided by the Standards for Reporting 
Implementation Studies statement.22 Ethical approval was provided by the Behavioural Research 
Ethics Board of the University of British Columbia and BC Women’s and Children’s Hospital.  
 
Setting 
Our study took place in the context of Canadian health care settings, which we defined as any 
service delivery environment where a prescriber could provide primary care, including hospitals, 
abortion facilities, health centres, and private physician offices, as well as via telemedicine.  
 
Participants 
Following Greenhalgh’s guidance,19 we sought to interview potential adopters and representatives 
of organizations that had an interest or concern in implementation of the innovation, mifepristone. 
Individuals eligible to participate in interviews included: a) physicians who intended to begin 
practice with mifepristone within the first year of availability; b) healthcare professionals, such as 




practice; and c) stakeholders who had the potential to impact health policy, system, and service 
factors that influence implementation of mifepristone (e.g. representatives of Health Canada, health 
care professional colleges, and advocacy groups). Participants had to be English- or French-
speaking and reside in Canada at the time of the interview in order to participate.  
 
Recruitment 
For physicians who intended to begin practice with mifepristone within the first year of availability, 
we invited those who completed a CART-Mife Study national online survey between January and 
December 2017 and responded that they would like to participate in an interview. All interview 
invitations and a copy of the consent form were sent by email to potential participants. We invited 
non-providing health care professionals and stakeholders via third-party recruitment with the 
assistance of the study’s knowledge user partners (e.g. health professional organizations). We also 
asked each non-providing physician if they would refer potential participants to the study 
(snowball recruitment). The potential study population was purposefully sampled to represent 
diversity of demographic characteristics (e.g., gender, age, profession, region), and factors related to 
implementation of mifepristone (e.g. previous abortion practice).  
 
Our sampling, data collection and analysis were iterative, rather than linear, steps to collect 
sufficient data to illustrate the phenomenon of mifepristone implementation in Canada. As 
categories emerged from analysis of transcripts, we engaged in theoretical sampling which guided 
our invitation of physicians to participate in a repeat interview 12 months later. Our sampling for 
repeat interviews was guided by the question: Given our emerging understanding of the factors 
that influence implementation, which participants would provide the most useful data to further 




information-rich cases of adoption or non-adoption. We also used stratified purposeful sampling 
(per above) to ensure that our repeat interview participants remained diverse and had varying 
experiences of abortion practice in the year following mifepristone availability.23  
 
Data Collection  
We developed and pilot tested our interview guide with a panel of researchers and clinicians prior 
to data collection (see Appendix 1). One-on-one semi-structured interviews were conducted by 
telephone in the first year of mifepristone availability at least 3 months after participants had 
completed training (April 2017 to December 2017). Repeat interviews were conducted one year 
later (October to December 2018). Three health services researchers (SM, EG, M-SW) conducted the 
interviews with support from a team of trainees from nursing, medicine, and population and public 
health (CD, MM, GL-R, KW, ESW, EZ). The trainees completed a full-day training workshop in the 
study procedures prior to engaging in data collection. During interviews, we sought to be attuned to 
the participants’ comfort level, and differences in power and status. Data collection and analysis 
were concurrent. We conducted interviews until we achieved saturation: when new data repeated 
what was in previous data (in our data collection), themes were well exemplified in participant data 
(in our sampling), and no new themes emerged (in our analysis).24,25 We also sought to recruit 
participants until our data sufficiently represented a range of the pre-identified factors from our 
purposeful sampling strategies. To ensure transparency and rigour, we engaged in verification 
strategies throughout, including constant comparison, keeping an audit trail, and sampling to 






Interviews were transcribed, and French interviews were translated to English, before two 
qualitative researchers (SM, ESW) subjected the data to thematic analysis, informed by Braun and 
Clarke’s flexible approach.26 We de-identified and coded a sample of transcripts independently and 
compared our results. Discrepancies were resolved through discussion with a third team member 
(WVN or EG). We developed a codebook inductively by identifying codes (themes) from the 
transcripts that were related to the research objectives and then mapped our themes to constructs 
in Diffusion of Innovation theory. We then explored individual, organizational, and system patterns, 
relationships, and interactions between the codes. To explain physicians’ implementation 
behaviour, we considered the frequency of themes across the data, presence of conflicting themes, 
and perceived relevance of the themes. Finally, we wrote the analysis into a descriptive, 
explanatory narrative that illuminated the factors influencing implementation of mifepristone 
abortion practice. 
Results 
We conducted one-on-one interviews with health care professionals (n=55) and stakeholders 
(n=35) involved in the planning and provision of abortion services in Canada. We conducted repeat 
interviews with 27 of the 55 health care professionals at least 12 months after their initial 
interview, to explore experiences of mifepristone provision. All 90 participants were volunteers 
and all who consented to participate completed their interview (see Table 1). Among those who had 
provided abortions prior to mifepristone’s availability, the experiences were diverse and ranged 
from writing one prescription for methotrexate-misoprostol to full-time surgical abortion practice. 
 
Participants’ perceptions of barriers and facilitators to implementation of mifepristone in routine 




Federal restrictions made mifepristone “more complicated than it needs to be”; 2) Navigating the 
“huge bureaucratic process” of organizational implementation; 3) Challenges with diffusion and 
dissemination of policy information; and 4) Adoption by individuals: “a process rather than an 
event”. Themes and representative quotations are provided in Appendix 2.  
 
1. Health Canada made mifepristone “more complicated than it needs to be” 
 
Participants’ interviews illuminated how Health Canada’s initial restrictions influenced their ability 
to implement the innovation, mifepristone, in routine care. In the first year of mifepristone 
availability (2017), all of Health Canada’s regulations for distribution of mifepristone were 
perceived to create unfeasible task issues that limited adoption of mifepristone abortion and in turn 
limited equitable access. While participants valued the knowledge from the online training 
modules, they also perceived training to be time-consuming and the registration with the 
manufacturer to be a breach of their privacy. Participants hypothesized that these factors would 
discourage other physicians from practice and thereby “limit women's access to medications” 
(006_Phys – family physician, Territories, previous medical and surgical abortion experience). 
 
New prescribers with limited prior abortion experience emphasized that the initial requirement for 
physician-only dispensing of mifepristone was inconsistent with their scope of practice and that in 
their experience dispensing was the responsibility of pharmacists. One noted, “I would definitely not 
have done this had they stuck to the original rules where we had to purchase, store all the products” 
(011_Phys – family physician, rural British Columbia, previous medical and surgical abortion 
experience). The requirement for ultrasound to be used for gestational age dating and to rule out 
ectopic pregnancy limited the ability of clinicians to provide mifepristone where they felt their local 




facilities perceived it to be an easy transition to prescribe mifepristone due to existing 
infrastructure, billing mechanisms, and skilled counselors.  
 
Participants were unanimous in their criticism of an initial requirement that mifepristone be a 
directly observed dosing, as one participant clarified, “I can’t think of a safety reason that is 
more significant for that medication than it is for tons of other things that are prescribed and 
taken at or from a pharmacy” (013_Phys – family physician, urban British Columbia, no 
previous abortion experience). This restriction was perceived as a paternalistic barrier to 
patient access, rather than a factor directly influencing clinician uptake. Although it remained 
in the product monograph initially, Health Canada removed this restriction before mifepristone 
became available in January 2017.27 In spite of this early policy change prior to the start of our 
study, a number of participants misbelieved that they had to observe their patients take the 
drug. 
 
2. Navigating the “huge bureaucratic process” of organizational implementation 
 
The majority of Health Canada’s federal restrictions were removed within the first year of 
availability (January-November 2017). Participants perceived that the “de-regulated” mifepristone 
regimen was simple and compatible with their primary care practice. However participants 
described persistent organizational barriers to implementing mifepristone in their local setting. 
Funding was a key challenge and included provincial variation in patient subsidies for the cost of 
the drug and in physician billing codes. Unequal costs and compensation across Canada created 
what participants described as a two-tiered system, where patients had financial access to surgical 
and medical options within one province, but in another they could face out-of-pocket charges only 




adding the billing code for medical abortion to their payment system, before they could begin to 
prescribe mifepristone (003_Phys – family physician, urban Ontario, previous medical and surgical 
abortion experience).  
 
Conscientious objection and anti-choice attitudes in organizations actively prevented physicians 
from implementing mifepristone abortion. Participants described hospital staff who refused to 
clean clinic rooms where abortion care was provided, hospital administrators who ignored 
requests to implement a medical abortion protocol, and community pharmacists who refused to 
dispense. These attitudes contributed to geographic variation in implementation of mifepristone.  
 
Experiences of stigma and harassment from the general public were uncommon: “it’s not like we 
have people demonstrating outside the hospital or clinic about abortions. It’s not to that degree. It’s 
more just the obstruction caused by people’s personal views” (040_Phys – family physician, rural 
British Columbia, previous medical abortion experience). While this did not impact participants’ 
willingness to implement mifepristone, it did influence how much they were willing to 
communicate or advertise their services as an abortion provider. To avoid scrutiny, some 
physicians chose to “do it kind of in the dark” and not to disclose their practice to family, friends, and 
colleagues (004_Phys – family physician, urban Ontario, no previous abortion experience).  
 
While universal coverage for mifepristone was established in Quebec during the first year of 
mifepristone’s availability in Canada, a separate policy process contributed an additional year of 
delay in making it available in this province. In addition, the Quebec College of Physicians added its 
own restriction requiring accredited training in surgical abortion for any mifepristone provider. 
While some participants felt that Quebec professional colleges were being unnecessarily restrictive 




mitigated if Health Canada had collaborated early on with provincial colleges to understand how 
regulations differed across provinces and territories (E8_Stakeholder & E9_Stakeholder – Quebec 
college/regulatory body decision makers). 
 
Participants reflected positively on the examples set by British Columbia and Ontario, provinces 
where professional colleges of pharmacy and medicine chose to overrule Health Canada’s 
restrictions soon after mifepristone’s approval and to allow pharmacists to dispense directly to 
patients. Participants perceived that the actions in BC and Ontario increased access and safety by 
supporting “doctors [to] do what they want using their own best medical discretion” 
(022_Stakeholder – national advocate). Participants described how such actions emboldened health 
professional regulators in other provinces to follow suit and ease restrictions on mifepristone 
dispensing. 
 
In rural communities, prescribers spoke about the realities of caring for patients who were 
distributed across vast geographic catchments and faced overwhelming barriers to access all 
primary care services, not just abortion. Some participants felt that it would be more feasible and 
private for many rural patients to access a single surgical abortion appointment compared to the 
multiple visits required for mifepristone medical abortion. Concerns about loss to follow-up for 
post-abortion care were strong for some participants. As one participant reflected, surgical 
abortion “is more certain. They make one trip to the city. It's a done deal. They go home. They don't 
have to follow up” (002_Stakeholder – advocate, Prairie province). Participants who were not 
concerned about potential complications said that having a “sounding board” of support from expert 





In spite of these implementation barriers at the organization level, prescribers felt that the tasks 
involved in providing mifepristone were relatively simple, compatible with their practice, and easy 
to learn through self-study. For instance, one prescriber who had never provided abortion before, 
was surprised at how straightforward it was and recalled thinking, “That was so crazy easy” 
(034_Phys – rural family physician, Atlantic province, no previous abortion experience).  
 
3. Challenges with diffusion and dissemination of policy information  
 
During the first year of availability, as Health Canada removed restrictions, participants struggled to 
make sense of rapidly changing and inconsistent information about the shifting regulations: 
 
“It seems almost every week there’s a new announcement about some kind of change in 
funding or regulation or all this sort of stuff that makes it very difficult as a provider to know 
what you can and can’t do. I actually think I don’t know why it has been rolled out this way, 
but I think it’s been made way more complicated than it needs to be.” (017_Phys – family 
physician, urban Ontario, previous medical and surgical abortion experience) 
 
Participants described how a regulatory change would be reported in the news media, but the 
product monograph would remain unchanged on existing stock. As one physician from urban 
Ontario reflected in the summer of the first year of mifepristone availability, “Is the pharmacist 
supposed to observe them taking the medication? Am I supposed to have the medication delivered to 
my office and then the patient come back? I don't actually, really, understand what the rule is there” 
(022_Phys – family physician, urban Ontario, previous medical abortion experience). Having peers 
on hand to act as “a sounding board” was critical, particularly for rural prescribers (040_Phys – 




still present in repeat interviews conducted with participants in the year after mifepristone was de-
regulated. 
 
Participants who were members of the community of practice component of our main study, the 
Canadian Abortion Providers Support (CAPS),28 consistently cited the platform’s bi-weekly emails 
as a reliable source of information on changing regulations. Nonetheless, participants expressed a 
need for more public communication about mifepristone as a new standard of care for family 
physicians to raise awareness among both practitioners and the public. These attitudes often were 
intertwined with the belief that these practitioners had a “responsibility” to support access to 
reproductive care (012_Stakeholder – advocate, Prairies). 
 
4. Adoption by individuals: ‘A process rather than an event’ 
 
Following Diffusion of Innovation theory, “adoption is a process rather than an event, with different 
concerns being dominant at different stages.”19 Factors related to individual physician behaviour – 
such as ability, skills, and motivation – influenced implementation of mifepristone in routine care. 
Pre-adoption, physicians first had to be aware of mifepristone, have up-to-date information about 
Health Canada’s changes, and have a clear perspective of how it would benefit their practice and 
patient population. During early use, participants’ confidence in prescribing increased as they 
honed their skills and knowledge with each successful abortion. One described how this led in turn 
to increasing the percentage of medical versus surgical abortions at their clinic: 
 
“Well, [the benefit] is already apparent to us. We have seen it on 250 patients thus far. That is 
more than we would see in an entire year when we were using methotrexate … Just seeing that, 




works. It makes me even angrier that it took this long to get, that women were denied this for 
so long.” (003_Stakeholder – facility leader, Prairie province) 
 
One key facilitator was participants’ perception of the ‘relative advantage’ of mifepristone in 
comparison to methotrexate medical abortion. They perceived that mifepristone was a more 
effective, reliable, and safe treatment. It also was seen to enhance access by allowing patients to 
manage their abortion in “their home at their convenience” (019_Stakeholder – advocate, British 
Columbia) and through primary care: “I think it puts access into family doctor's hands because it's a 
lot more within our realm than going on and doing training in surgical abortions” (004_Phys– family 
physician, urban Ontario, no previous abortion experience). Our repeat interviews with 
participants suggested providing even one medical abortion strengthened these attitudes. 
 
Participants viewed mifepristone as the new best practice for medical abortion in Canada, which 
was a motivator to start providing. As one family physician reflected, “Like I said, it’s the standard of 
care for the physicians” (038_Phys – family physician, rural British Columbia, no previous abortion 
experience). Our repeat interviews indicated that many family physicians in the sample became 
motivated to provide mifepristone after getting a well-timed nudge, such as counselling a patient 
with an unplanned pregnancy or hearing a colleague’s experience of prescribing. However, a 
sample of urban physicians who did not yet prescribe mifepristone expressed that they were 
experiencing “inertia” (042_Phys – family physician, urban British Columbia, previous medical 
abortion experience) and would prefer the convenience of continuing to refer their patients to 
nearby abortion clinics. For these non-prescribers, the key pre-adoption barrier was a perception 







Main Findings  
We undertook a national qualitative investigation of physicians’ and stakeholders’ perceptions of 
the factors influencing implementation of mifepristone medical abortion during its first two years 
of availability in Canada. Our results indicate that uptake was initially challenging due to 
restrictions contained in federal approval of mifepristone; however within the first year of 
availability (January-November 2017) these restrictions were removed and mifepristone could be 
prescribed in primary care settings and dispensed in pharmacies (see Box 1). Despite the de-
regulation of mifepristone at the federal level, a number of barriers persisted throughout the study 
period at the organizational and individual levels which made it difficult to implement in primary 
care. These barriers included provincial variation in patient subsidies and physician billing codes, 
provincial restrictions from the Quebec College of Physicians, and lack of motivation to provide 
mifepristone among some family physicians who assumed that abortion was already accessible in 
their communities. Ongoing implementation of mifepristone will require Canadian organizations to 
create tailored solutions to these local barriers, which may include creating new billing codes, 
provincial policy advocacy efforts in Quebec, and conducting physician engagement to raise 
awareness of access barriers. Reflecting the variation in regulations between provinces, 
perceptions of barriers were lower in British Columbia, Ontario, and Alberta, and highest in Quebec, 
where availability was further delayed. In spite of these barriers, participants held strong 
perceptions that mifepristone was the new standard of care for medical abortion in Canada and 






Our results are consistent with research in high-income nations, which documents that federal 
regulations are barriers to uptake of mifepristone.12,29,30 Participants in our study who did not 
intend to engage in medical abortion expressed a sense of ‘inertia’ similar to those reported by 
Australian general practitioners, who perceived that abortion is a service provided in specialist 
clinics, and that abortion will draw unwanted stigma.  Our results suggest providers may 
incorrectly perceive medical abortion risks to be greater than those related to continued pregnancy, 
despite strong evidence to the contrary.1,32–34 Loss to follow-up may occur in 10-20% of medical 
abortion cases.  However, international studies have demonstrated that severe complications are 
rare.1,36  
 
Our research may have important implications for the U.S., where a number of the restrictions that 
Health Canada repealed are still mandated nationwide. The U.S. Risk Evaluation and Mitigation 
Strategy (REMS) for mifepristone includes elements to ensure safe use of the drug: 1) pharmacists 
cannot dispense directly to patients, 2) prescribers must be registered with the drug distributor, 
and 3) patients must sign a mandated “agreement” form.14 Our results demonstrate that Canadian 
physicians perceived these elements would not enhance safety, would discourage other physicians 
from practice, and would limit access to abortion. The experience of implementing mifepristone in 
the absence of regulations will be relevant for jurisdictions like the U.S., and may be useful in efforts 





Strengths and Limitations 
Our results will have relevance for other high-income nations where medical abortion is provided 
in primary care settings. Canada’s experience illustrates how evidence-based deregulation of 
mifepristone may facilitate its provision and increase access. Strengths of our study are our 
national sample, interviews conducted at two time points, and inclusion of new and experienced 
abortion providers, physicians not involved in abortion services, and stakeholders responsible for 
rural and urban family planning services. These stakeholders are ideally positioned to reflect on the 
factors that influence uptake of medical abortion at an individual, organizational, and system level. 
An additional strength of this national sample is our inclusion of experiences of practitioners from 
regions with historically limited abortion access, including the Territories and Atlantic provinces. 
Our results may be limited by including only one nurse practitioner in the sample, who became 
eligible to provide medical abortion during the study. In future research, our team will explore their 
perspectives, as well as those of midwives, patients, and pharmacists. We investigated mifepristone 
implementation in its early phase, during which Health Canada made significant changes to the 
regulation of this drug. As use and familiarity with mifepristone increase, the barriers and 
facilitators will likely change.  
 
Conclusion 
In the first two years since mifepristone has been made available in Canada, rapid regulatory 
revisions greatly assisted primary care practitioners to implement abortion care, particularly in 
rural communities. These changes have led to health care professional perceptions that there are 
minimal regulatory barriers to medical abortion practice. Our results are unique internationally as 
Canada is the first nation to facilitate provision of medical abortion in primary care settings through 
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Table 1: Characteristics of participants 
 
Characteristics  No. (n=90) 
Profession  
Family Physician / General Practice 45 
Gynaecologist 8 
Other primary health care professional* 2 
Stakeholder  
College or regulatory body 13 
Advocate or advocacy group 9 
Government  7 




British Columbia 19 
Prairies (Alberta, Saskatchewan, Manitoba) 14 
Ontario 14 
Quebec 20 
Atlantic (New Brunswick, Nova Scotia, Newfoundland) 9 
Territories (Yukon, Northwest Territories, Nunavut) 5 
Total 90 






Other/did not respond 2 
Total 90 







Health care professional practice location (n=55)  
Urban 33 
Rural 22 
Total  55 
Health care professional abortion experience at time of 
study enrollment (n=55) 
 
Both 24 
Surgical only 9 




* Other primary health care professional (e.g. nurse practitioner, emergency medicine) 
** Participants reported collectively from some provinces and territories to protect anonymity due 




Box 1.  Changes to Health Canada regulations for mifepristone-misoprostol medical 
abortion, as of January 2020 
Topic Change Date changed 
Observed ingestion Removed requirement for observation of 
mifepristone ingestion. The patient can take 
the medication where and when they choose. 
October 2016 
Training Removed requirement for training for 
pharmacists. 
May 2017 
Training Removed requirement for training for 
prescribers. 
November 2017 
Consent form Removed requirement for a manufacturer 
consent form to be signed by the patient. 
November 2017 
Registration Removed requirement for registration of 
prescribers or pharmacists with the 
manufacturer. 
November 2017 
Dispensing  Mifepristone can be dispensed directly to 
patients by a pharmacist or prescribing 
health professional, rather than the original 
requirement that a physician must dispense 
directly to the patient. 
November 2017 
Gestational age Mifepristone-misoprostol may be used up to 
nine weeks (63 days) from last menstrual 






Ultrasound Removed requirement for mandatory 







Appendix 1: Interview Guides 
 
Interview Guide A 
Physician initial interview (3 months after training to prescribe mifepristone) 
 
To begin, please tell me about your practice setting and your role in it. 
1. Can you please tell me about your experience with mifepristone so far?  
a. How many mifepristone terminations have you provided to date? 
b. How does that compare to the number of terminations you typically provide using 
other methods?   
2. What is your past experience with abortion care? (Probe for type of abortion services 
available) 
3. What do you feel are the advantages of mifepristone as a new treatment? 
a. Do you see there being any downsides to having mifepristone available in Canada? 
4. How do other providers in your community feel about mifepristone and abortion care? 
a. What are your relationships like with other key people in your community? (Such as 
other providers, pharmacists, managers) 
b. Do/Did you have a formal plan for implementing mifepristone in your community? 
What does it look like? 
c. Can you describe the patient care pathway for mifepristone medical abortion in your 
practice? (Such as appointments, prescribing, dispensing, and where and how each 
step takes place)  
 
I would like to talk a little more about any obstacles you have faced in providing mifepristone. 
5. What things make it challenging to provide? Has _________ been a factor? (How?) 
 Cost (such as provincial coverage, financial disincentives, uncertainty about coverage) 
 Billing codes (such as lack of billing codes; lack of compensation) 
 Clinical workflow (such as counselling; following up; changing from a surgical to a 
medical abortion clinic; time pressure) 
 Documentation (such as Health Canada forms, consent forms) 
 Drug availability and dispensing (such as ordering it) 
 Government support (such as political factors) 
 Regulations (such as physician dispensing) 
 Community presence of anti-choice attitudes (such as among protestors or colleagues) 
 Having access to surgery, ultrasound, or labs 
 Human resources (such as counsellors; staff burn out) 
 Availability of information (such as confusion about regulations; where to get 
training; where to get updates) 
 Training (such as the requirement to get training) 
 
6. What changes would make it easier for you to provide mifepristone? 
Let’s talk about your experience with the training program: 
 
7. What made you decide to take the mifepristone training program? 
8. What was your experience of the training process? 
a. How easy or difficult was it to get the training? 




typically do professional development? 
c. How could the training be improved? 
 
I would also like to know about any support or feedback you are receiving. We spoke earlier about 
your relationships with your colleagues in your community.  
 
9. Are there any key individuals that have rallied to support mifepristone, either in your 
community or elsewhere in Canada? Can you describe what they did? 
a. Is there any person or organization you would describe as unsupportive? (What did 
they do?) 
10. Have you exchanged information with anyone about mifepristone, either inside or outside 
of your setting?  
a. What did that look like? (For instance, have you spoken to the media or contacted your 
college registrar?)  
b. Have you learned about any changes to mifepristone regulations or coverage? What 
have you learned? Where did you get the information? 
11. Are you a member of the Canadian Abortion Providers Support platform, also known as the 
“CAPS” website? 
a. If YES: Tell me your thoughts about it. / What do you like or dislike about the website? 
/ How can it be improved? 
b. If NO, explain what the website is before following up: Would joining this website be 
useful for you? (Why / why not?) / To help us make it useful for you, what information 
would you want from the website?  
12. What do you like about other communities of practice that you belong to, such as email list 
serves? 
13. How will you know that you are achieving good outcomes with mifepristone in your 
community? 
 
I have come to the end of my questions. 
14. Is there anything else you think I should know? 






Interview Guide B 
Healthcare professionals, such as family physicians, who were eligible to become mifepristone 
prescribers but did not pursue this practice 
 
 
1. Please tell me about your practice setting and your role in the past 12 months. 
a. What are the areas of focus for your clinical practice? 
2. Can you please tell me what you know about medical abortion and the new abortion pill 
called mifepristone? 
3. What do you feel are the advantages of the new abortion pill? 
a. Do you see there being any downsides to having the abortion pill available in Canada? 
4. Have you ever provided abortion care before? Can you please describe the care you 
provided? 
a. How do you feel about abortion? 
5. Are you aware of the Society of Obstetricians and Gynaecologists of Canada mifepristone 
training program for physicians and pharmacists?  
a. If YES: Tell me your thoughts about it.  
b. If NO, explain what the training is before following up: Would taking this training be 
useful for you? (Why / why not?)  
6. Can you describe the abortion care available in your practice setting or community? 
7. How do other providers in your community feel about the abortion pill? 
a. What are your relationships like with other key people in your community who would 
be involved in providing the abortion pill? (Such as other physicians, pharmacists, 
managers) 
b. What are your relationships like with abortion providers? 
c. What relationships or networks do you feel are necessary for you to provide the 
abortion pill? 
d. Do you have a formal plan for implementing the abortion pill in your community? Do 
you know of anyone else’s plans? What does they look like? 
8. Are there any key individuals that have been leaders in implementing the abortion pill, 
either in your community or elsewhere in Canada? Can you describe what they did? 
a. Is there any person or organization you would describe as unsupportive? (What did 
they do?) 
9. Have you exchanged information with anyone about the abortion pill, either inside or 
outside of your setting?  
a. What did that look like? (For instance, have you spoken to the media or contacted your 
college registrar?)  
b. Have you learned about any changes to abortion pill regulations or coverage? What 
have you learned? Where did you get the information? 
 
I would like to talk a little more about any factors that may be an obstacle for you to providing the 
abortion pill. 
10. Has _______ been a factor? (How?)  
 Cost (such as provincial coverage, financial disincentives, uncertainty about coverage) 
 Billing codes (such as lack of billing codes; lack of compensation) 
 Clinical workflow (such as counselling; following up; changing from a surgical to a 
medical abortion clinic; time pressure) 
 Documentation (such as Health Canada forms, consent forms) 




 Government support (such as political factors) 
 Regulations (such as physician dispensing) 
 Community presence of anti-choice attitudes (such as among protestors or colleagues) 
 Having access to surgery, ultrasound, or labs 
 Human resources (such as counsellors; staff burn out) 
 Availability of information (such as confusion about regulations; where to get training; 
where to get updates) 
 Training (such as the requirement to get training) 
 
11. Would you ever consider providing medical abortion with mifepristone? 
a. If YES: What changes would make it easier for you to provide? 
i. Probe for changes to their personal opinions; professional support; training; 
policies and regulations; practical aspects of practice 
a. If NO: Why? 
 
12. What support or feedback would be necessary for you to practice mifepristone medical 
abortion? 
13. Are you aware of the Canadian Abortion Providers Support platform, also known as the 
“CAPS” website? 
a. If YES: Tell me your thoughts about it. 
b. If NO, explain what the website is before following up: Would joining this website be 
useful for you? (Why / why not?) / To help us make it useful for you, what information 
would you want from the website?  
14. How will you know that the abortion pill is well received and used in your province?  
 
I have come to the end of my questions. 
 
15. Is there anything else you think I should know? 
16. Do you have any questions for me? 





Interview Guide C 
Physician repeat interview (12 months after initial interview) 
 
1. Please tell me about your experience since our interview on [Month/Date]. 
a. Have you begun to prescribe mifepristone? Why / Why not? 
b. Have others in your community begun to prescribe mifepristone? 
  
If they provide mifepristone: 
 
2. Can you describe the patient care pathway for mifepristone medical abortion in your 
practice? (Such as appointments, prescribing, dispensing, and where and how each step 
takes place)  
 
I would like to talk a little more about any obstacles you have faced in providing mifepristone. 
 
3. In our last interview, you said that these things have been a factor for you in providing 
mifepristone: [list factors] I’m going to go through each of these one at a time.  
4. Is _________ still a factor for you? (How? What has changed? Why?)  
a. [Probe about new factors that emerged from data collection and analysis after the 
participant’s interview] 
5. Are there any other changes that would make it easier for you to provide mifepristone? 
 
I would also like to know about any support or feedback you are receiving.  
 
6. Since our last interview, have you exchanged information with anyone about 
mifepristone, either inside or outside of your community?  
7. Have you learned about any changes to mifepristone regulations or coverage? What 
have you learned? Where did you get the information? 
8. Are you a member of the Canadian Abortion Providers Support platform, also known as 
the “CAPS” website? 
a. If YES: Tell me your thoughts about it. / What do you like or dislike about the 
website? / How can it be improved? 
b. If NO: Why did you choose not to join the CAPS website? 
 
I have come to the end of my questions. 
 
9. Is there anything else you think I should know? 





Interview Guide D 
Stakeholders 
 
1. Please tell me about your role and your organization. 
2. How long have you been in this role? 
3. From your perspective, please tell me the story of how mifepristone came to be in Canada. 
4. When did you first get involved with bringing mifepristone to Canada? What has your role 
been?  
5. Tell me about your understanding of the rules and regulations set by Health Canada. 
6. Tell me about your understanding of the rules and regulations set by your regulatory body. 
7. Tell me your process for implementing mifepristone in your organization/setting.  
8. How have those processes changed since approval?  
9. What would you have done differently? 
10. What have the challenges been? Probe for the following and for factors that emerge from 
data collection/analysis with physicians: 
 Cost / Financial disincentives / Coverage 
 Pharmacy stock 
 Access to surgery, ultrasound, labs 
 Government support 
 Regulations (product monograph, Risk Management Plan, training) 
 Human resources (i.e. turnover, burnout) 
11. What has reduced those challenges? 
12. What needs to change to make it easier to implement mifepristone in your setting? 
13. Who are the different groups involved in implementing mifepristone? What have they 
done? 
14. Tell me about how you have engaged with other groups? Probe for the following: 
 Key individual, experts 
 Degree of support (or unsupportive) 
 Degree of communication 
 Quality of information exchange 
 Feedback with the media 
15. Can you tell me about your organization’s values and how they relate to mifepristone? 
16. What are the advantages of mifepristone as a new treatment?  
17. Can you describe any potential downsides to implementing mifepristone?  
18. How will you know that you are achieving good outcomes with implementing mifepristone?  
a. What kind of outcomes are you tracking or looking for or look for? \ 
b. How do you measure successful implementation of Mife? 
19. Is there anyone else you recommend I speak with?  
20. Is there anything else you think I should know?  






Appendix 2: Themes and Representative Quotations 
 
 
Table 1: Federal restrictions made mifepristone “more complicated than it needs to be” 
Physicians’ ability to implement mifepristone in routine care was influenced by federal restrictions 






required to complete a 
training program 
 X “It [the training] is going to limit women's access to 
medications. It might be a person, for example -- I've 
seen this – where they're intent to do this module, but 
they just haven't gotten around to it. Then suddenly you 
have a patient there who wants a medical, and they just 
don't have the time to do it, to go through the module 
and get the prescribing right. That’s a barrier versus if 
you could prescribe the medication and then get some 
mentorship by someone who has experience with using 
the medication, which is kind of how we use all of our 
medications.” 006_Phys – family physician from the 
Territories, previous medical and surgical abortion 
experience 
 Prescribers and 
dispensers were 
required to certify 
their identity with the 
manufacturer 
 X “Until recently, we had to get registered with the 
company as [abortion] prescribers, and I really was 
uncomfortable with that. We did it, but I really hated the 
notion that a private corporation has my name, address, 
and information. If they get hacked, that information 
could be potentially accessed, if there was a data 
breach.” 035_Phys – primary care professional from the 








 X “We’re not set up to dispense medications from our 
office. We wouldn't have been able to dispense it just 
through the clinic that I work in. I think, that’s better, 
that it’s not dispensed by physicians. I don't know of 
any other medication that is dispensed by physicians.” 
036_Phys – rural Saskatchewan family physician, 
previous medical and surgical abortion experience 
 Prescribers were 
required to provide 24 
hour on-call follow up 
for patients 
 X “The sort of requirement to be available on call is no fun 
because that is not traditionally how I practice. I've 
basically gotten a second phone just to use for on call, 
which is a nuisance. I don't want to give my private cell 
number, but I don't have a call service. Traditionally I 
don't have to do after hours … it bugs me that we're 
expected to be on call for free, forever” 029_Phys – rural 







 X “I know we had groups to talk to us that said, ‘This is 
ridiculous. Women shouldn’t be walking around with 
their informed consent and giving that to the pharmacy 
to the prescription filled.’ We said, ‘What are you talking 
about?’ There was information out there that it was a 
requirement from Health Canada, which was not the 
case. When we heard that that was an option to have 




the pharmacy, we didn’t think that was a good idea. We 
actually rejected that. We said, ‘We don’t think for 
various privacy concerns that that’s appropriate.’” 
007_Stakeholder – government decision maker 
 Requirement to watch 
the patient ingest the 
drug 
 X “I’ve never seen any other drug – and we’ve prescribed 
lots of toxic, horrible things – that had to be given by the 
doctor directly and watch the patient take the dose.” 
008_Phys – rural Saskatchewan family physician, no 
previous abortion experience 
 
“It was interpreted to mean that the patient would have 
to be in the presence of a doctor, in front of the doctor 
to take the drug, which was kind of unheard of for any 
drug to be handled that way. It was perceived as being 
very paternalistic; ’Women can’t be trusted.’” 
022_Stakeholder – national advocate 
 Gestational age limit 
was lower than 
recommended by 
guidelines 
 X “I mean, the Health Canada original guideline really 
conflicted with the SOGC guideline in what the evidence 
stated. … There is strong evidence that Mife is good up 
to nine, 10 weeks. I think that that is something that I 
would be willing to do and other providers at our 
facility would too.” 015_Phys – urban Saskatchewan 
family physician, previous medical and surgical abortion 
experience 




 X “Right now, an ultrasound is required. Maybe that can 
soften too. If this woman has regular periods at exactly 
every 28 or 30 days or whatever their period is, they 
had a normal, regular period, and now they are 
pregnant and now are starting to get sore breasts. If you 
are in a remote community where ultrasound is not 
accessible, maybe you can actually trust women.” 
020_Phys – urban Ontario family physician, previous 





of mifepristone in 
Canada was “slow” 
 X “I was thrilled that it was going to be approved. I felt 
like it was a long time coming.” 030_Phys – urban 
Ontario family physician, previous surgical abortion 
experience 
 
“It just seemed like Health Canada was a little bit slow. 
Kind of like mifepristone was regulated in a way that 
almost no other drug that I use as a family physician is 
regulated, right?” 015_Phys – urban Saskatchewan family 
physician, previous medical and surgical abortion 
experience 
 Federal politics and 
policies influenced the 
approval process 
X  “The original application was initiated during the 
Conservative government, so they [the distributor] 
were probably strategically positioning that application 
in a way that would have been a bit more palatable for 
acceptance, or they were hoping would not have the 
resistance, but now that we have a supportive federal 
government in place and don’t expect that kind of 
resistance and certainly have been working hard with 
Health Canada, etc., you know. There’s some back work 




strategies and approaches.” 008_Stakeholder – 
government decision maker 






Table 2: Navigating the “huge bureaucratic process” of organizational implementation 
Physicians’ ability to implement mifepristone in routine care was influenced by health system and 
structural factors 
Theme Description F B Quotation 
Billing and costs Physician 
compensation for 
medical abortion 
X X “I don't even have a billing code for telemedicine. I don't 
have a billing code for medical abortions. I don't have a 
billing code for ultrasounds out-of-hospital. I don't have 
a billing code for any of the counselling that we do … 
Suggesting that introducing Mife is just all of a sudden 
going to increase regional access to abortion, I think, is 
egotistical of people.” 005_Phys – urban New Brunswick 





X X “I think the biggest thing is cost. That’s the hugest thing. 
To offer women, ‘Here you can have a medication 
abortion or a surgical procedure’ and say, ‘The surgical 
procedure is free, but you have to pay $325’ — or 
whatever it is — ‘for your medication abortion,’ I think 
that’s not giving a, it’s not a real choice. I think that’s a 
problem.” 001_Phys – rural British Columbia family 






 X “We’re part of a hospital. There’s a huge bureaucratic 
process that I have had very little to do with 
implementing. I’m just going to just wait and apply with 
it when it becomes [available] … Once we do, it’ll just be 
part of routine care.” 003_Phys – urban Ontario family 
physician, previous medical and surgical abortion 
experience 
 
“I would love to be able to [prescribe]. That’s not in my 
realm of decision making ... I’ve asked at our meeting 
what could potentially be happening. I asked that kind of 
directly to the [Department Head], and they kind of said 
they really haven’t heard anything yet and more 
information should be maybe forthcoming, so that’s the 
last I’ve heard from them. I plan to bring it up again in 
our next meeting” 025_Phys – rural Nova Scotia family 
physician, no previous abortion experience 
 Moving ahead in 
some provinces, 
while lagging 
behind in others  
X  “The College of Physicians and Surgeons and College of 
Pharmacists in Ontario and BC have basically come out 
with statements telling their members that you can, 
basically, ignore the Health Canada requirements. You 
don't have to do an ultrasound unless you think it is 
necessary … pharmacists can now dispense directly to 
patients. We have gotten rid of that requirement or that 
expectation, at least, in those two provinces.” 
022_Stakeholder – national advocate 
 
“Well, firstly, I think the big mistake was wanting to 
bring in the Mife abortion pill to Quebec, as it was done 
in the rest of Canada. Secondly, Quebec is not only 
different in terms of the number of abortion services, but 




all the powers, even in Quebec. The Collège des 
médecins is the other party that one must work with to 
develop this type of thing.” Stakeholder E4 – facility 
leader 
Rural care Population and 
resource needs of 
rural communities 
 X “Yesterday, I did a surgical termination on a woman who 
had to travel literally 12 hours from the northern part of 
the province for a surgical procedure. I kept thinking, 
you know, if there had been a provider in her 
community or a nurse practitioner who could have done 
a medical. She had to leave four children in a community 
that's 12 hours away, right?” 002_Phys – rural British 








 X “There is the assumption that you have speedy 
laboratory and access to ultrasound. That just isn’t 
always the case because when we do have an ultrasound 
tech, it’s usually a long list. Doing a dating ultrasound is 
pretty low priority for most of the things that are out 
there.” 026_Phys – rural family physician from the 
Territories, previous medical and surgical abortion 
experience 
 
“My experience with medical abortions done with 
methotrexate and misoprostol is it’s something you 
want to make sure is covered but not because you ever 
need it, but because you might need it. So access to 
urgent D&C, for instance, if need be, would be important, 
but the truth is with any place where they’re going to 
have miscarriages, which is everywhere, would also 
have to have access to those services, so it’s no more of 
an issue for this than it is for a miscarriage.” 
016_Stakeholder – College/regulatory body decision 
maker 
 Finding ways to 
stock and dispense 
the drug 
 X “Initially, it seemed to be that I would have to order 
them, pay, and charge the patient, and they may or may 
not get it reimbursed from the insurance. I think if I had 
to go through that process, that would be difficult in 
sorting out, ‘How am I going to be stocking this in my 
office? How am I going to charge patients?’ From my 
understanding, that has been eased, and I can actually 
just prescribe it.” 004_Phys – urban Ontario family 
physician, no previous abortion experience 
 Getting experience 
with the tasks of a 
new practice 
X  “I’ve prescribed it, I think, only once … I had the perfect 
patient come into my office who I knew would be a 
candidate, so we scrambled to get the investigations 
done. I spent a summer weekend doing the online 
training and then prescribed it. The pharmacy was really 
open to doing it. They were like, ‘Yeah, we were meaning 
to ask you if we should do this.’ I was like, ‘I’ve been 
meaning to ask you guys if we should do this,’ so we did, 
and it was textbook. She was the perfect candidate. It 
went perfectly. No problems. No hitches, and it was 
great.” 034_Phys – rural Nova Scotia family physician, no 




 Task shifting from a 
surgical to medical 
abortion practice 
X X “We were so surgically focused, when we got around to 
dedicating a whole day to doing medical abortions 
because the demand was that high, we didn’t really lay 
off staff because we have so many casual people. We had 
to reorganize our day so that instead of having five 
nurses on, we only needed one. That was a bit of a 
change for the clinic. Moving forward, if we have to do 
more of that, then that will be a significant change for 
this site because we have been organized as a surgical 
facility, and we will end up being more like a doctor's 
office.” 003_Stakeholder – abortion facility administrator 
 Patient counselling X  “We’re not trained counsellors, and we are often pressed 
for time. Again, in our dream world, we would have a 
counsellor on site as well, so the woman could see us 
and also a counsellor.” 031_Phys – family physician from 
the Territories, previous medical and surgical abortion 
experience 
 Patient follow-up  X “We have many patients that come from different cities, 
up to an hour, an hour and a half away. We would love to 
do some of the follow-up just over the phone, so they 
physically don’t have to come in, but we do not have a 
way of getting the blood work in other facilities. The 
only way we can do it is have them physically come to 
the hospital to have that done. That was another 
obstacle.” 028_Phys – urban Ontario family physician, 
previous medical and surgical abortion experience 







Table. 3: Challenges with diffusion and dissemination of policy information 
Physicians’ ability to implement mifepristone in routine care was influenced by communication and 
interaction with colleagues, advocacy groups, and news media 
Theme Description F B Quotation 
Collegiality  Collaboration with 
peers, consultants, and 
pharmacists to make 
implementation work 
X  “We do a lot of just ‘off the side of our desk’ medicine 
in a rural setting, so when you do something for the 
first or second time or you don’t do it very often, it’s 
good to have other medical colleagues you can run 
something by or say, ‘What do you think of this? Is 
this crazy? Do you have any other ideas?’ That is huge 
for me when I’m trying something new or doing 
something new just to have others around me that 
maybe don’t have a lot more experience than me but 
that are supportive and a good sounding board.” 
040_Phys – rural British Columbia family physician, 
previous medical abortion experience 
 Having a mentor X  “We just had an e-mail come round through the 
Division of Family Practice from the obstetrician in 
[city] who does the unplanned pregnancy clinic 
saying she sees these women coming to her from 
here, and she knows it’s difficult, and can she support 
us in getting started [with mifepristone], and do we 
want a session? I replied, ‘Yes, I absolutely would love 
that.’ That would actually be the thing that would 
nudge me over the edge I think would just be to have 
that personal contact.” 039_Phys – rural British 
Columbia family physician, no previous abortion 
experience 





 X “I think it’s good for people to wait a little bit and not 
kind of jump in because it gets confusing … I kind of 
want to wait until some other changes happen so I 
can say, ‘This is how it is. You don’t need pharmacists 
to do this. Physicians aren’t required to do this,’ or 
whatever because to undo information will be a lot 
harder.” 008_Stakeholder – government decision 
maker 
 Availability of a 
community of practice 
for quality information  
X  “I think it [the Canadian Abortion Providers Support 
(CAPS) platform] is a fantastic resource because it has 
a lot of information on how to provide services, on 
where to find pharmacists. I like the fact that it is a 
sort of members only website, at least some parts of 
it. I think there’s been a lot of design going into 
making that a safe and non-hackable space … It’s sort 
of a nice centralized way of getting information and 
distributing information to the people who are among 
the providers.” 021_Phys – urban British Columbia OB-
GYN, previous medical and surgical abortion 
experience 
 Awareness of 
mifepristone as a new 
option   
 X “I don’t think patients know about it, but it’s even 
more important for doctors. I don’t think doctors 
know about it, ones who aren’t watching for it. For 
me, it was on my radar because it was interesting to 




your average person. I have a particular interest in it, 
right?” 008_Phys – rural Saskatchewan family 
physician, no previous abortion experience 
 
“I did speak to the owner of the pharmacy that we 
deal with all the time about it being on the market. 
She didn't even know what it was. When I was saying, 
‘Mifegymiso is now available.’ She said, ‘What is that?’ 
I said, ‘It is the abortion pill.’ She was like, ‘I had never 
heard of it.’” 020_Stakeholder – Atlantic province 
abortion facility administrator 
Being an 
advocate 
The role of advocacy in 
improving access to 
family planning 
services 
X  “I think what people don’t understand is if a woman 
wants to terminate a pregnancy, she will. That means 
that she will even do it illegally or dangerously, and 
she will terminate that pregnancy. What we are going 
to see if there are any cutbacks on abortion services, 
we are going to see injured and sick and even dead 
women. That’s why I feel that I am more resolved to 
provide those services.” 033_Phys – urban Ontario OB-
GYN, no previous abortion experience 
Anti-choice 
attitudes 
Avoiding scrutiny as an 
“abortion doctor”  
 X “Some of them that are abortion providers basically 
have to sneak their way into the clinic so people 
picketing outside don't see them or they don’t let 
their extended family know that they are abortion 
providers. You certainly know that people that are 
living their life doing this don’t feel like they can do it 
openly, which is unfortunate if you look at the 
support that there actually is amongst Canadians, that 
we still have to be doing it kind of in the dark.” 





 X “The reason we don’t do abortions at our hospital is 
essentially because of the insurmountable anti-choice 
elements among the staff. We would have cleaning 
people who wouldn’t clean the OR. We would have 
nurses who wouldn't participate in the case. We 
would have a number of anaesthetists who wouldn't 
provide any kind of anaesthesia backup for the OBs 
who were doing abortions before at our hospital … 
We can’t even start talking about Mife until we start 
talking about just accepting abortion as a whole.” 
005_Phys – urban New Brunswick family physician, 
previous medical and surgical abortion experience 






Table 4: Adoption by individuals: ‘A process rather than an event’ 
Physicians’ ability, motivation, and skills to implement mifepristone in routine care 








X  “It’s way more predictable than methotrexate and 
misoprostol. It’s been much easier to use in my very 
limited experience, but even just talking to other people 
who have been using it, it’s been much easier to use. I 
think there’s going to be much more uptake from 
physicians who weren’t normally providing abortions 
before but who will be open to do it because of the 
relative ease of using the mifepristone” 006_Phys – 
family physician from the Territories, previous medical 
and surgical abortion experience 
 Patients experience 
more comfort, 
options, and access 
with mifepristone  
X  “I think there’s huge benefits for the patient’s 
convenience. I think in terms of being able to manage 
this in a primary care environment, including their home 
at their convenience, not when a surgeon is available or 
not. I think the patient has a lot control over the 
situation, so I see it as a huge benefit.” 019_Stakeholder – 
Advocate 
Motivation Experiencing 
motivation to start 
providing 
X  “I had intentions of doing it [the training] … but then I 
had a referral with a patient requesting it, so that 
prompted me to get the certification done so that I 
would be able to do my best to provide that for her.” 
032_Phys – rural Saskatchewan OB-GYN, previous surgical 
abortion experience 
 Experiencing 
“inertia” (waiting to 
start providing) 
 X “Knowing that there’s all these fast-changing 
regulations, especially knowing that the pharmacy-
training piece was going to fall away eventually is part of 
why I waited … I’m more hopeful now that I will be able 
to convince the pharmacists in the community to stock 
it.” 021_Phys – urban British Columbia OB-GYN, previous 
medical and surgical abortion experience 
 Assuming there is 
good access and the 
service is not 
needed  
 X “The availability is there. It’s kind of mainly my own 
inertia … I feel like it’s such a low barrier, but to be 
honest with you, it’s an even lower barrier that I have 
my patients be seen by [an abortion clinic] across the 
street.” 042_Phys – urban British Columbia family 
physician, previous medical abortion experience 




X  “We were very nervous to do medicals on people who 
were out in rural without much support, but we’ve 
moved increasingly to … being a lot less nervous about 
that. With Mife, our results are going to better, quicker, 
and more assured. That’s going to be even less a 
constraint. [What caused that shift that made you less 
nervous?] I think experience.” 018_Phys – urban 
Saskatchewan family physician, previous medical and 
surgical abortion experience 
Reinforcement  Observing patient 
satisfaction and 
drug effectiveness 
X  “I see the same patients all the time. That patient, I’ve 
seen her three times since. She hugs me every time. She’s 
so happy. That’s a thing. You see, I would see them again 
and again and again because it’s a small, defined 




good outcome, I will know about that, too. In that way, 
it’s very easy.” 034_Phys – rural Nova Scotia family 
physician, no previous abortion experience 
F: Facilitator; B: Barrier 
 
 
 
